Cassava Sciences Retires Chief Medical Officer, Appoints Jack Moore

Cassava Sciences announced the upcoming retirement of its Chief Medical Officer, Dr. James W. Kupiec, effective May 9, 2025, after his notable contributions to the company's Alzheimer's disease clinical trial program. In his place, Dr. Jack Moore has been appointed as Senior Vice President of Clinical Development, starting April 28, 2025. Dr. Moore brings extensive experience in central nervous system disorders from previous roles at leading pharmaceutical companies and will focus on advancing the clinical evaluation of simufilam, particularly for new indications such as tuberous sclerosis complex (TSC)-related epilepsy. The leadership transition is part of a broader strategic shift aimed at expanding Cassava's therapeutic pipeline. Despite facing financial challenges and stock volatility, Cassava remains committed to developing novel treatments for CNS disorders, with simufilam as a central asset. The company’s renewed leadership and focus on strategic partnerships highlight efforts to bolster its clinical development and future growth prospects.